Theravance Biopharma has appointed Richard Graham as Senior Director, Clinical Pharmacology. Graham joins Theravance from Onyx Pharmaceuticals, where he served as Senior Director, Head of Clinical Pharmacology. Previously, he served as Senior Scientist, Clinical Pharmacology at Genentech; earlier positions at Genentech include: Scientist, Clinical Pharmacology and Associate Scientist, Early Development PK/PD. Prior, Graham served in various roles at GlaxoSmithKline including: Principal Scientist, Infectious Disease CEDD DMPK; Senior Scientist, Metabolic and Viral CEDD DMPK; and, Consultant, Metabolic and Viral CEDD DMPK.

Graham received his B.S. and M.S. in Biochemistry and Biophysics from Iowa State University and his Ph.D. in Molecular Pharmaceutics from University of North Carolina at Chapel Hill.

About Theravance Biopharma

The mission of Theravance Biopharma (NASDAQ: TBPH) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIVĀ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made byGlaxo Group Limited or one of its affiliates ("GSK") pursuant to its agreements with Innoviva, Inc. (formerly Theravance, Inc.) relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium and vilanterol (the "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.